ArticleJournal of medical virology2021
Clinical exacerbation of SARS-CoV2 infection after fingolimod withdrawal.
Article in Journal of medical virology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.
- COVID-19 and disease-modifying therapies in patients with demyelinating diseases of the central nervous system: A systematic review.Multiple sclerosis and related disorders · 2021Pooled it
- The effect of Fingolimod on patients with moderate to severe COVID-19.Pharmacology research & perspectives · 2023Trial
- Clinical Outcomes of Hospitalized Immunocompromised Patients With COVID-19 and the Impact of Hyperinflammation: A Retrospective Cohort Study.Journal of inflammation research · 2025Article
- Knowledge mapping of COVID-19 and autoimmune diseases: a visual and bibliometric analysis.Clinical and experimental medicine · 2023Article
- The Sphingolipid-Signaling Pathway as a Modulator of Infection by SARS-CoV-2.Current issues in molecular biology · 2023Review
- Potential treatments of COVID-19: Drug repurposing and therapeutic interventions.Journal of pharmacological sciences · 2023Review
- Will Omics Biotechnologies Save Us from Future Pandemics? Lessons from COVID-19 for Vaccinomics and Adversomics.Biomedicines · 2022Review
- Prognostic markers for the clinical course in the blood of patients with SARS-CoV-2 infection.European journal of medical research · 2022Article
- Computational pharmacology: New avenues for COVID-19 therapeutics search and better preparedness for future pandemic crises.Biophysical chemistry · 2022Article
- Potential role of marine species-derived bioactive agents in the management of SARS-CoV-2 infection.Future microbiology · 2021Article
- Atrioventricular block after fingolimod resumption: a consequence of sphingosine-1-phosphate axis alteration due to COVID-19?Journal of neurology · 2021Article
- Anti-inflammatory Therapy by Cholinergic and Purinergic Modulation in Multiple Sclerosis Associated with SARS-CoV-2 Infection.Molecular neurobiology · 2021Review
- Immunology of COVID-19 and disease-modifying therapies: The good, the bad and the unknown.European journal of neurology · 2021Review
- A New England COVID-19 Registry of Patients With CNS Demyelinating Disease: A Pilot Analysis.Neurology(R) neuroimmunology & neuroinflammation · 2021Article
- Multiple Sclerosis, Disease-Modifying Therapies and COVID-19: A Systematic Review on Immune Response and Vaccination Recommendations.Vaccines · 2021Review
- Role of the SphK-S1P-S1PRs pathway in invasion of the nervous system by SARS-CoV-2 infection.Clinical and experimental pharmacology & physiology · 2021Review
- COVID-19, anorexia nervosa and obese patients with an eating disorder - some considerations for practitioners and researchers.Journal of eating disorders · 2021Article
- Clinical exacerbation of SARS-CoV2 infection after fingolimod withdrawal.Journal of medical virology · 2021Article
- An Overview of the Efficacy and Safety of Ozanimod for the Treatment of Relapsing Multiple Sclerosis.Drug design, development and therapy · 2021Review
- Rationale for the use of sphingosine analogues in COVID-19 patients.Clinical medicine (London, England) · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The role of disease-modifying therapies in patients with autoimmune disorders during severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) infection is controversial. Immunocompromised patients could have a more severe coronavirus disease-2019 (COVID-19) due to the absence of an adequate immune response against the SARS-CoV-2. However, therapies that act on immune response could play a protective role by dampening the cytokine-release syndrome. Fingolimod is a drug used for immune therapy in patients with multiple sclerosis (MS) through the sequestration of activated lymphocytes in the lymph nodes. We report the case of a 57-year-old man with relapsing-remitting MS treated with fingolimod that showed a reactivation of COVID-19 with signs of hyperinflammation syndrome after fingolimod withdrawal. Our case suggests that discontinuation of fingolimod during COVID-19 could imply a worsening of SARS-CoV2 infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.